Dopaminergic and cholinergic interaction in cataleptic responses in mice

Pharmacology Biochemistry and Behavior

Volumn 58, Issue 1, 1997, Pages 103-108

  Ushijima, I ^a   Kawano, M ^a   Kaneyuki, H ^a   Suetsugi, M ^a   Usami, K ^a   Hirano, H ^a   Mizuki, Y ^a   Yamada, M ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Catalepsy; Haloperidol; Mice; Physostigmine; Pilocarpine; SCH23390

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; CHOLINESTERASE INHIBITOR; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M1 RECEPTOR ANTAGONIST; PHYSOSTIGMINE; PILOCARPINE; PIRENZEPINE; RECEPTOR SUBTYPE; SCOPOLAMINE;

ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; APOMORPHINE; CATALEPSY; CHOLINERGIC ANTAGONISTS; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; HALOPERIDOL; MALE; MICE; MICE, INBRED STRAINS; PARASYMPATHETIC NERVOUS SYSTEM; PARASYMPATHOMIMETICS; PHYSOSTIGMINE; PILOCARPINE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, MUSCARINIC; SCOPOLAMINE;

ANIMALIA;

EID: 0030746963     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(96)00478-9     Document Type: Article

References (26)

1. Balsara J. J., Bapat T. R., Gada V. P., Chandorkar A. G. Small doses of apomorphine induce catalepsy and antagonize methamphetamine stereotypy in rats. Psychopharmacologia. 78:1982;192-194.
2. 3H]205-501, a non-catechol dopaminergic agonist, labels selectively and with high affinity dopamine D2 receptors. J. Neural. Transm. 62:1985;231-248.
3. Costall B., Naylor R. J. Olley, J. E Catalepsy and circling behaviour after intracerebral injections of neuroleptic, cholinergic and anticholinergic agents into caudate-putamen, globus pallidus and substantia nigra of rat brain. Neuropharmacology. 11:1972;645-663.
4. Ellenbroek B., Schwarz M., Sontag K. H., Jaspers R., Cools A. Muscular rigidity and delineation of a dopamine specific neostriatal subregion. Tonic EMG activity in rats Brain Res. 3456:1985;132-140.
5. Gershanik O., Heikkila R. E., Duvoisin R. C. Behavioral correlations of dopamine receptor activation. Neurology. 33:1983;1489-1492.
6. Gianutsos G., Lal H. Modification of apomorphine-induced aggression by changing cholinergic activity in rats. Neuropharmacology. 16:1977;7-10.
7. Hartgraves L. L., Kelly P. H Role of mesencephalic reticular formation in cholinergic-induced catalepsy and anticholinergic reversal of neuroleptic-induced catalepsy. Brain Res. 307:1984;47-54.
8. Jackson D. M., Hashizume M. Bromocriptine induces marked locomotor stimulation in dopamine-depleted mice when D1 dopamine receptors are stimulated with SKF38393. Psychopharmacology. 90:1986;147-149.
9. Klemm W. R. Evidence for a cholinergic role in haloperidol-induced catalepsy. Psychopharmacology. 85:1985;139-142.
10. Klemm W. R. Drug effects on active immobility responses. What they tell us about neurotransmitter systems and motor functions Prog. Neurobiol. 32:1989;403-422.
11. Meller E., Kuga S., Friedhoff A. J., Goldstein M. Selective D2 dopamine receptor agonists prevent catalepsy induced by SCH23390, a selective D1 antagonist. Life Sci. 36:1985;1857-1864.
12. Morelli M., Di Chiara G. Catalepsy induced by a SCH23390 in rats. Eur. J. Pharmacol. 117:1985;179-185.
13. Nylander I., Terenius L. H. Dopaminergic receptors mediate alterations in striato-nigral dynorphin and substance P pathways. Neuropharmacology. 26:1987;1295-1302.
14. Ögren S. O., Fuxe K. D1 and D2 receptor antagonists induce catalepsy via different striatal pathway. Neurosci. Lett. 85:1988;333-338.
15. Pifl C., Reither H., Hornykiewicz O. Lower efficacy of the dopamine D1 agonist, SKF38393, to stimulate adenylyl cyclase activity in primate than in rodent striatum. Eur. J. Pharmacol. 202:1991;273-276.
16. Roth R. H., Bunney B. S. Interaction of cholinergic neurons with other chemically defined neuronal systems in the CNS. Goldberg A. M., Hanin I. Biology of cholinergic function. 1976;379-394 Raven, New York.
17. Seeman P. Brain dopamine receptors. Pharmacol Rev. 32:1981;229-313.
18. Setler P. E., Sarau H. M., Zirkle C. L., Saunders H. L. The central effects of a novel dopamine agonist. Eur. J. Pharmacol. 50:1978;419-430.
19. 2 receptors Pharmacol. Biochem. Behav. 33:1989;41-44.
20. Undie A. S., Friedman E. Differences in the cataleptogenic actions of SCH23390 and selected classical neuroleptics. Psychopharmacology. 96:1988;311-316.
21. Ushijima I., Horita A. Cocaine. Evidence for NMDA- and opioid-mediated antinociception in the tail-flick test Pharmacol. Biochem. Behav. 44:1993;365-370.
22. Ushijima I., Mizuki Y., Yamada M. Multifocal sites of action involved in dopaminergic-cholinergic neuronal interactions in yawning. Psychopharmacology. 95:1988;34-37.
23. Ushijima I., Mizuki Y., Yamada M. Development of tolerance and reverse tolerance to haloperidol- and SCH23390-induced cataleptic effects during withdrawal periods after long-term treatment. Pharmacol. Biochem. Behav. 50:1995;259-264.
24. Wanibuchi F., Usuda S. Synergistic effects between D1 and D2 dopamine antagonists on catalepsy in rats. Psychopharmacology. 102:1990;339-342.
25. White F. J., Bednarz L., Wachtel S. R., Hjorth S., Brooderson R. Is stimulation of both D1 and D2 receptors necessary for the expression of dopamine-mediated behaviours. Pharmacol. Biochem. Behav. 30:1988;189-193.
26. Yamada K., Furukawa T. Direct evidence for involvement of dopaminergic inhibition and cholinergic activation in yawning. Psychopharmacology. 67:1980;39-43.